Brief: Camurus: Positive Phase 3 Results From Acroinnova 2 Study Of Octreotide SC Depot (Cam2029) In Acromegaly Patients
15/07/2024 06:41
July 15 (Reuters) - Camurus AB CAMX.ST :
* ANNOUNCES POSITIVE PHASE 3 RESULTS FROM ACROINNOVA 2 STUDY
OF
OCTREOTIDE SC DEPOT (CAM2029) IN ACROMEGALY PATIENTS
* TREATMENT WELL TOLERATED WITH A SAFETY PROFILE CONSISTENT
WITH
STANDARD-OF-CARE (SOC)
Source text for Eikon: ID:nWkr83WMpV
Further company coverage: CAMX.ST
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))
Recent news on Camurus AB
See all newsBrief: Camurus Receives Approval In Canada For Oczyesa XR
Brief: Executive Sells About £279,000 Of Camurus Shares
Jefferies cuts Ipsen to 'underperform' on Somatuline competition risk
Brief: Camurus Says NDA Resubmission For CAM2029 In Acromegaly Accepted For Review By FDA
Camurus shares rise after Q2 revenue, operating profit beat